How GLP-2 and GIP Increase Blood Flow to the Intestines — And It's Not Through the Pathways Scientists Expected

Both GLP-2 and GIP independently increased blood flow through the superior mesenteric artery (the main blood vessel feeding the intestines) in anesthetized rats. Surprisingly, this effect did not depend on nitric oxide or vasoactive intestinal peptide — two of the most commonly assumed mediators of gut blood flow. Combining the two peptides or using a novel dual GIP/GLP-2 co-agonist did not produce a synergistic (greater-than-additive) effect. The GLP-2 receptor antagonist GLP-2(3-33) successfully blocked GLP-2's blood flow effect, confirming it acts through the GLP-2 receptor.

Researchers used anesthetized male Sprague-Dawley rats with transit-time flow probes surgically placed on the superior mesenteric artery to directly measure blood flow in real time. They administered GLP-2, GIP, or a novel dual co-agonist and measured acute blood flow changes. To test potential mechanisms, they pre-treated rats with a nitric oxide synthase inhibitor (L-NAME) or a VIP receptor antagonist before giving the peptides. They also tested the GLP-2 receptor antagonist GLP-2(3-33).

After you eat a meal, blood flow to your intestines increases dramatically to help absorb nutrients. GLP-2 and GIP are gut hormones released after eating that were suspected of driving this response, but the mechanism wasn't clear. This study confirms both peptides boost intestinal blood flow and — importantly — rules out two of the most obvious pathways (nitric oxide and VIP), meaning there's an unknown mechanism at work. Understanding this could be relevant for conditions like short bowel syndrome, where GLP-2 analogs are already used as drugs.

GLP-2 is already the basis of an FDA-approved drug — teduglutide (Gattex) — used to treat short bowel syndrome by promoting intestinal growth and nutrient absorption. Understanding how GLP-2 increases blood flow to the gut adds another piece to the puzzle of how this peptide works therapeutically. The finding that the mechanism is independent of nitric oxide is particularly surprising, since NO-mediated vasodilation is one of the best-understood pathways in vascular biology. Identifying the actual mechanism could lead to better-targeted therapies for gut diseases.

This was an animal study in anesthetized rats, which may not fully reflect how these peptides work in awake animals or humans. Anesthesia itself can affect cardiovascular responses. The study used male rats only, so sex-specific differences weren't explored. The doses used were pharmacological rather than physiological, and the acute timeframe doesn't capture longer-term vascular adaptations.